Zeller presents its R&D expertise at Phytopharm 2018

Research and development (R&D) is essential to establish phyto-pharmaceuticals that meet the highest standards of modern medicine. R&D not only helps to develop a broad range of important new medicines, but also to maximize efficacy, safety and tolerability of existing drugs.

Zeller’s commitment to science is evident through its high investment in R&D, which accounts for about 15% annual turnover. Additionally, Zeller works closely in collaboration with universities such as ETH Zurich, University of Marburg and University of Bonn to improve the pharmacology and clinical benefit of its products. Through the enormous research efforts, the herbal medicine of Zeller belongs to the modern evidence-based, rational phyto-therapy.

One of the latest activities of Zeller is to support the Phytopharm Congress in Horgen, Switzerland, from 25th to 27th of June 2018. At this congress, organized by the St. Petersburg Institute of Pharmacy and Zurich University of Applied Sciences (ZHAW), experts from all over the world will give the most recent insights into medicinal plants research, phyto-chemistry and phyto-therapy.

Part of the congress programme will be an excursion to Zeller head offices in Romanshorn and VitaPlant AG, a subsidiary of Zeller, to learn more about the development of evidence-based phyto-pharmaceuticals.

At the Phytopharm Congress, Zeller will share its latest research results with the phyto-community. Various lectures and posters with new research data will be presented by academic collaborators and Zeller staff:

• Prof. Hanns Häberlein (University of Bonn, Germany): “Membrane-bound receptors: Changes in plasma membrane lipid composition affect membrane fluidity and receptor status”
• Prof. Dietrich Ober (University of Kiel, Germany): “Spatiotemporal aspects of pyrrolizidine alkaloid biosynthesis – Chances for a better understanding of PA-producing plants.”
• Malena Rabenau (University of Marburg, Germany): “Effects of Cimicifuga racemosa extract Ze 450 on mitochondrial resilience in neurons and liver cells”
• Dr. Simon Nicolussi (Zeller): “Effect of CIMicifuga racemosa on metabolic parameters in women with menopausal symptoms – a retrospective cohort study (CIMBOLIC)”
• Samuel Hasler (ETH Zurich & Zeller): “Involvement of AMPK activation in the mechanism of effect of Ze 450 and Ze 339”
• Dr. Bettina Nägele (Zeller): “Validation of analytical methods for quality assurance in phytopharmacy – HPTLC technique as an example”
• Prof. Jürgen Drewe (Zeller): “Anti-inflammatory effects of the P. hybridus extract Ze 339 are mediated by inhibition of the STAT pathway”

To hear about Zeller’s latest research results, we welcome you to participate at the Phytopharm Congress 2018 in Switzerland. Please visit www.phytopharm2018.ch for registration.